ECR launches sleep aid product, Zolpimist Oral Spray in the US

NovaDel Pharma Inc. (OTC BB: NVDL) today announced that Zolpimist Oral Spray has been launched in the United States by ECR Pharmaceuticals, a subsidiary of Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK). ECR Pharmaceuticals announced the immediate availability of Zolpimist Oral Spray, a novel delivery system of the most widely prescribed sleep aid in the US, zolpidem tartrate. The Zolpimist Oral Spray unit contains 60 metered sprays and provides the flexibility of administering either a 5 or 10 mg dose of the zolpidem active ingredient. As with most prescription hypnotic agents, Zolpimist Oral Spray is federally classified as a CIV controlled substance. Zolpimist is only available by prescription.

Steven B. Ratoff, Chairman and CEO, said, "We are pleased to have Zolpimist available in the US marketplace." Hi-Tech President and CEO David Seltzer indicated that, "Zolpimist is a significant addition to ECR, our branded products subsidiary, and reflects our continuing commitment to build this segment of our business through the marketing of widely used, innovative products." Over 79 million prescriptions are written annually in the US for sleep aid products.